(Q50876843)

24 March 2018

title

Long-term 4-year safety of saxagliptin in drug-naive and metformin-treated patients with Type 2 diabetes. (English)

1 reference

24 March 2018

0 references

1 reference

J Rosenstock

1

1 reference

24 March 2018

J L Gross

2

1 reference

24 March 2018

C Aguilar-Salinas

3

1 reference

24 March 2018

M Hissa

4

1 reference

24 March 2018

N Berglind

5

1 reference

24 March 2018

S Ravichandran

6

1 reference

24 March 2018

D Fleming

7

1 reference

24 March 2018

publication date

19 July 2013

1 reference

24 March 2018

published in

Diabetic Medicine

1 reference

24 March 2018

volume

30

1 reference

24 March 2018

issue

12

1 reference

24 March 2018

page(s)

1472-1476

1 reference

24 March 2018

Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial

cites work

1 reference

Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin.

21 January 2018

1 reference

Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone

21 January 2018

1 reference

Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.

21 January 2018

1 reference

Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes

21 January 2018

1 reference

Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes

21 January 2018

1 reference

The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone

21 January 2018

1 reference

Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial

21 January 2018

1 reference

Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks.

21 January 2018

1 reference

Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/DME.12267

1 reference

24 March 2018

PubMed ID

23802840

1 reference

24 March 2018